Joshua Richter, MD, discusses the evolving treatment landscape in relapsed/refractory multiple myeloma.
EP. 1: Overview of Multiple Myeloma and Treatment Options
Joshua Richter, MD, gives an overview of treatment options in multiple myeloma and factors that influence treatment decisions.
EP. 2: Role of Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Expert oncologist Joshua Richter, MD, defines triple-class refractory multiple myeloma and describes selinexor’s unique mechanism of action.
EP. 3: Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple-Class Refractory MM
An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.
EP. 4: Bispecific Antibodies in the Treatment of Multiple Myeloma
An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.
EP. 5: Clinical Pearls and Unmet Needs in R/R Multiple Myeloma
Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.
EP. 6: Recap: Selinexor as a Treatment Option in Relapsed/Refractory Multiple Myeloma
Joshua Richter, MD, discusses the optimal use of selinexor in the treatment of relapsed/refractory multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512